Biolife Solutions Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $106.7M+42.9% YoYTTM through 30 Jun 2026
Net Income $58MTTM through 30 Jun 2026
Free Cash Flow $8.1MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 64.0% |
| EBITDA Margin | 3.2% |
| Operating Margin | 0.1% |
| Net Margin | 54.4% |
Returns
-3.1%ROE
13.0%ROA
-0.1%ROIC
Balance Sheet Health
Debt / Equity0.04x
Current Ratio7.30x
Net Debt-$96.6Mnet cash position
Cash & Equivalents$24M
Quality Metrics
Altman Z-Score40.31
Piotroski F-Score5 / 9
FCF Margin7.6%
Rule of 4015.6
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $96.2M
Diluted EPS$1.18TTMFY2025: $-0.09
Dividend
No dividend
Capital Allocation
R&D Spend$9.8M
Capex Intensity8.2%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.